A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) C. Verslype et al.   ANNALS OF ONCOLOGY

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

(2012) C.M. Britten et al.   IMMUNITY

Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression

(2012) Brian F. Zamarron et al.   International Journal of Biological Sciences

Interaction of tumor cells with the microenvironment

(2011) Hendrik Ungefroren et al.   Cell Communication and Signaling

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Immune Responses in Hepatocellular Carcinoma

(2010) Firouzeh Korangy et al.   DIGESTIVE DISEASES

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma

(2008) Daniel H. Palmer et al.   HEPATOLOGY